Plasmid-based CRISPR-Cas9 system efficacy for introducing targeted mutations in CD81 gene of MDA-MB-231 cell line | Zendy

Kasra Arbabi Zaboli | Zendy; Hossein Rahimi | Zendy; Jose Thekkiniath | Zendy; Amir Hossein Taromchi | Zendy; Saeed Kaboli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasmid-based CRISPR-Cas9 system efficacy for introducing targeted mutations in CD81 gene of MDA-MB-231 cell line

Author(s) -

Kasra Arbabi Zaboli,

Hossein Rahimi,

Jose Thekkiniath,

Amir Hossein Taromchi,

Saeed Kaboli

Publication year - 2022

Publication title -

folia histochemica et cytobiologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.384

H-Index - 40

eISSN - 1897-5631

pISSN - 0239-8508

DOI - 10.5603/fhc.a2022.0007

Subject(s) - crispr , cas9 , biology , plasmid , genome editing , exon , cd81 , gene , subgenomic mrna , computational biology , genetics , microbiology and biotechnology , hepatitis c virus , virus

Breast cancer has been represented a challenging issue worldwide as it is one of the major leading causes of death among women. CD81 gene, a member of the tetraspanin protein family, has been associated with the development of human cancers. Genome editing technologies, particularly the CRISPR-Cas9 system, have shown rapid progress in gene function studies. In this study, we aimed to evaluate the ability of the CRISPR-Cas9 plasmid-based system to modify specific regions of the CD81 gene in the MDA-MB-231 breast cancer cell line.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research